Main Newsletter
Mastery Series
Therapy Series
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Type 2 DiabetesSGLT2Issue 730

AACE: Invokana May Be Effective Monotherapy for T2DM Control

The SGLT2 inhibitor canagliflozin could help type 2 diabetes patients who fail to control their disease with diet and exercise.... 


At a late-breaking session of the American Association of Clinical Endocrinologists meeting, William Canovatchel, MD, Janssen Pharmaceuticals, presented data showing that in a phase III study, patients had significantly greater reductions in HbA1c with either of two doses of canagliflozin compared with those on placebo (P<0.001 for both).

Canagliflozin has been shown in several studies to reduce HbA1c, body weight, and blood pressure, and has been generally used as an add-on therapy when patients fail other antihyperglycemic agents such as metformin.

To assess its efficacy as monotherapy in patients whose type 2 diabetes isn't controlled with diet and exercise alone, Canovatchel and colleagues enrolled 584 patients in a 26-week trial.

They were randomized to placebo or to one of two doses of canagliflozin (100 mg or 300 mg) and the primary endpoint was change in HbA1c. The secondary endpoint was change in body weight from baseline.

Overall, the researchers found significantly higher reductions in HbA1c with both doses of the drug compared with placebo:

  • 100 mg: -0.91% (P<0.001)
  • 300 mg: -1.16% (P<0.001)

They also saw a significantly greater change in body weight in both drug groups compared with placebo:

  • 100 mg: -2.2%, -1.9 kg (P<0.001)
  • 300 mg: -3.3%, -2.9 kg (P<0.001)

For the composite endpoint of A1c and body weight taken together, the researchers found that more than 70% of patients treated with the 100-mg dose and 80% of those in the 300-mg group had a reduction in both A1c and body weight compared with only 28% of those on placebo.

In terms of safety, there were similar proportions of adverse events across all three groups, in about 53% of those on placebo, 61% of those on the 100-mg dose, and 60% of those in the 300-mg group.

The well-established side effect of genital mycotic infections was also seen in this trial, with 2.5% of men in the 100-mg dose and 5.6% of men in the 300-mg group experiencing such infections compared with none of the men on placebo. For women in the placebo group, only 3.8% had infections compared with 8.8% of those on the 100-mg dose and 7.4% of those in the 300-mg group. There was no significant increase in hypoglycemia with the drug, occurring in 2.6% of those on placebo, 3.6% of those in the 100-mg group, and 3% of those in the 300-mg group.

Canovatchel concluded that for type 2 diabetes patients who failed diet and exercise, canagliflozin is associated with significant reductions in both HbA1c and body weight compared with placebo -- and that the findings suggest the SGLT2-inhibitor may be an effective monotherapy, which "may impact the selection of therapeutics for type 2 diabetes management."

Practice Pearls:
  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Overall, the researchers found significantly higher reductions in HbA1c with both doses of the drug compared with placebo

AACE- Source reference: Canovatchel W, et al "Canagliflozin monotherapy provides reductions in a composite measure of A1c and body weight in patients with type 2 diabetes mellitus" AACE 2014.



Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  Type 2 DiabetesSGLT2Issue 730

Past five issues: Issue 752 | SGLT-2 Inhibitors Special Edition October 2014 | Diabetes Clinical Mastery Series Issue 211 | Issue 751 | Humulin Insulin Special Edition October 2014 |

2014 Most Popular Articles:

FDA Approves Once-Weekly GLP-1 Diabetes Treatment Regimen for T2DM
Posted September 25, 2014
Stanley Schwartz, MD: A New Way of Classifying Diabetes - The Beta-Cell Centric Approach
Posted September 29, 2014
Two Positive Phase 3 Trials for ITCA 650, a GLP-1 Agonist, in Type 2 Diabetes
Posted October 10, 2014
Best Insulin Regimen for Type 1's
Posted October 10, 2014
EASD: Insulin Pumps Lower Mortality Rate 29% Compared to Multiple Injections in T1DM
Posted October 03, 2014
New GLP-1 Receptor Agonist as an Alternative to Insulin Glargine?
Posted October 10, 2014
Handbook of Diabetes, 4th Ed., Excerpt #13: Control and Complications
Posted October 13, 2014
Non-Caloric Artificial Sweeteners May Induce Glucose Intolerance
Posted October 10, 2014
Adding an SGLT2 to Insulin Improved Control
Posted October 17, 2014
GLP-1 Agonist Medications Chart
Posted September 23, 2014

Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Are your patients getting enough glucose strips to manage their diabetes?
CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75

Search Articles On Diabetes In Control